DGAP-News: Neovacs S.A. signs a cooperation agreement with the Department Immunology of Diabetes at the reputed Hospital Cochin in Paris

GERMANY


DGAP-News: Neovacs S.A. / Key word(s): Alliance
Neovacs S.A. signs a cooperation agreement with the Department Immunology of
Diabetes at the reputed Hospital Cochin in Paris

12.10.2016 / 11:05
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE  (  PRESS RELEASE  (  PRESS RELEASE

NEOVACS SIGNS A COOPERATION AGREEMENT WITH
 THE DEPARTMENT IMMUNOLOGY OF DIABETES AT THE REPUTED HOSPITAL COCHIN IN
PARIS

To collaborate on development of new diabetes treatment using Neovacs'
Kinoid Technology

Paris, October 12, 2016 - NEOVACS (Alternext Paris: ALNEV PEA-PME
eligible), a leader in active immunotherapies for the treatment of
autoimmune diseases, today announced a collaboration with Doctor Agnès
Lehuen and Professor Christian Boitard, who are leading the laboratory for
Research in Immunology of Diabetes at the reputated Cochin Hospital in
Paris. The goal of this collaboration is to achieve proof of concept for
the use of Neovacs' IFNa Kinoid in the treatment of Type 1 diabetes.

As part of this collaboration, Doctor Lehuen and Professor Boitard's teams
will jointly conduct research with scientists from Neovacs on INFa Kinoid
in NOD models (Non-Obese Diabetic mice - the most relevant mouse model for
this disorder). Existing scientific publications offer a significant body
of evidence to support the involvement of IFNa in Type 1 diabetes . This
preclinical study aims to determine whether the use of the IFNa Kinoid
vaccine can control this disorder by producing polyclonal neutralizing
antibodies to Interferon alpha.

Neovacs has already demonstrated in a Phase I /II study in lupus that anti-
interferon antibodies have a biological activity capable of neutralizing
the IFN signature, with a long-term positive effect . The same principle
could be applied in Type 1 diabetes, which is an autoimmune disease also
having an IFNa signature as observed in Lupus, and characterized by an
overexpression of this cytokine (IFN alpha).

According to Miguel Sieler, CEO of Neovacs: "This collaboration confirms
the interest in our technology and its potential. It also supports our
confidence in the development of therapeutic vaccines, especially with our
INFa kinoid. We are very pleased to work with the Cochin Hospital teams in
the Department of Immunology of Diabetes. It is urgent to address the unmet
medical needs associated with Type 1 diabetes, and we believe that our
technology has the potential to meet the expectations of the scientific
community in this field. We are confident that this collaboration will
produce actionable results and will provide important answers about
developing a targeted treatment for Type 1 diabetes, responding to the
concerns of patients."

Dr. Agnes Lehuen and Professor Christian Boitard also explained: "This
collaboration with Neovacs fits perfectly into our research focus. Indeed,
faced with the rapid increase in patients affected by Type 1 diabetes, we
need to find innovative ways to treat this disease and Neovacs' approach is
particularly interesting."


About Diabetes
Diabetes is a disease that affects, according to WHO**, 422 million people
worldwide, including 4 million in France and a rapid progression that could
include 622 million patients by 2040. Notably, 10% of these patients have
the auto immune form of type 1 diabetes.

** Source: World Report on Diabetes, published by WHO, April 2016

About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused
on an active immunotherapy technology platform (Kinoids) with applications
in autoimmune and/or inflammatory diseases. On the basis of the company's
proprietary technology for inducing a polyclonal immune response (covered
by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy
being developed for the indication of lupus. Neovacs is also conducting
preclinical development works on other therapeutic vaccines in the fields
of auto-immune diseases, oncology and allergies. The goal of the Kinoid
approach is to enable patients to have access to safe treatments with
efficacy that is sustained in these life-long diseases.

For more information on Neovacs, please visit www.neovacs.fr

Contacts

NEOVACS       
Charlène Masson      
+33 (0)1 53 10 93 00   
cmasson@neovacs.com

Investor Relations -
Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-210228-30
raimund.gabriel@mc-services.eu


---------------------------------------------------------------------------

12.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

   Language:    English                                                   
   Company:     Neovacs S.A.                                              
                3-5, Impasse Reille                                       
                75014 Paris                                               
                France                                                    
   Phone:       +33 (0)1 53 10 93 00                                      
   Fax:         +33 (0)1 53 10 93 03                                      
   E-mail:      www.neovacs.fr                                            
   Internet:    info@neovacs.fr                                           
   ISIN:        FR0004032746                                              
   WKN:         A1CVKR                                                    
   Listed:      Regulated Unofficial Market in Stuttgart; Open Market in  
                Frankfurt                                                 
 
 
   End of News    DGAP News Service  
---------------------------------------------------------------------------

511027 12.10.2016